September 27, 2022
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology
Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”)…
Read more
September 08, 2022
콘테라파마와 BDD 파마 간 파킨슨병의 야간 증상 및 아침 무동증 치료를 위한 새로운 정제 제형 개발 계약 체결
Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, has entered into collaboration with BDD Pharma, a drug delivery…
Read more